Tumor-suppressive MiR-218-5p Inhibits Cancer Cell Proliferation and Migration Via EGFR in Non-small Cell Lung Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Apr 9

PMID 27057632

Citations 47

Authors

Kegan Zhu

Hanying Ding

Wengong Wang

Zhicong Liao

Zheng Fu

Yeting Hong

Yong Zhou

Chen-Yu Zhang

Xi Chen

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. Recently, microRNAs (miRNAs) have been consistently demonstrated to be involved in NSCLC and to act as either tumor oncogenes or tumor suppressors. In this study, we identified a specific binding site for miR-218-5p in the 3'-untranslated region of the epidermal growth factor receptor (EGFR). We further experimentally validated miR-218-5p as a direct regulator of EGFR. We also identified an inverse correlation between miR-218-5p and EGFR protein levels in NSCLC tissue samples. Moreover, we demonstrated that miR-218-5p plays a critical role in suppressing the proliferation and migration of lung cancer cells probably by binding to EGFR. Finally, we examined the function of miR-218-5p in vivo and revealed that miR-218-5p exerts an anti-tumor effect by negatively regulating EGFR in a xenograft mouse model. Taken together, the results of this study highlight an important role for miR-218-5p in the regulation of EGFR in NSCLC and may open new avenues for future lung cancer therapies.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.

The modulation of immune cell death in connection to microRNAs and natural products.

Chuang Y, Yen C, Tang J, Chang F, Tsai Y, Wu K Front Immunol. 2025; 15:1425602.

PMID: 39759512 PMC: 11695430. DOI: 10.3389/fimmu.2024.1425602.

Non-coding RNAs and exosomal non-coding RNAs in lung cancer: insights into their functions.

Lv X, Yang L, Xie Y, Momeni M Front Cell Dev Biol. 2024; 12:1397788.

PMID: 38859962 PMC: 11163066. DOI: 10.3389/fcell.2024.1397788.

Toxicological Aspects Associated with Consumption from Electronic Nicotine Delivery System (ENDS): Focus on Heavy Metals Exposure and Cancer Risk.

Granata S, Vivarelli F, Morosini C, Canistro D, Paolini M, Fairclough L Int J Mol Sci. 2024; 25(5).

PMID: 38473984 PMC: 10931729. DOI: 10.3390/ijms25052737.

Non-Coding RNAs as Key Regulators in Lung Cancer.

Gilyazova I, Gimalova G, Nizamova A, Galimova E, Ishbulatova E, Pavlov V Int J Mol Sci. 2024; 25(1).

PMID: 38203731 PMC: 10778604. DOI: 10.3390/ijms25010560.

References

Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y . MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013; 190(3):1059-68. DOI: 10.1016/j.juro.2013.02.089. View

Kumar M, Erkeland S, Pester R, Chen C, Ebert M, Sharp P . Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008; 105(10):3903-8. PMC: 2268826. DOI: 10.1073/pnas.0712321105. View

Miska E . How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005; 15(5):563-8. DOI: 10.1016/j.gde.2005.08.005. View

Arteaga C . ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003; 284(1):122-30. DOI: 10.1016/s0014-4827(02)00104-0. View

Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J . MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. Tumour Biol. 2015; 36(10):8015-23. DOI: 10.1007/s13277-015-3532-x. View

de Jong J, van Diest P, van der Valk P, Baak J . Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol. 1998; 184(1):53-7. DOI: 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7. View

Pan Y, Liang H, Chen W, Zhang H, Wang N, Wang F . microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. RNA Biol. 2015; 12(3):276-89. PMC: 4615722. DOI: 10.1080/15476286.2015.1017208. View

Lindow M, Kauppinen S . Discovering the first microRNA-targeted drug. J Cell Biol. 2012; 199(3):407-12. PMC: 3483128. DOI: 10.1083/jcb.201208082. View

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K . The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006; 9(6):485-95. DOI: 10.1016/j.ccr.2006.04.022. View

10.

Baselga J . Targeting tyrosine kinases in cancer: the second wave. Science. 2006; 312(5777):1175-8. DOI: 10.1126/science.1125951. View

11.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S . MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010; 6(3):e1000879. PMC: 2837402. DOI: 10.1371/journal.pgen.1000879. View

12.

Dienstmann R, Martinez P, Felip E . Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget. 2011; 2(3):165-77. PMC: 3260814. DOI: 10.18632/oncotarget.245. View

13.

Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S . Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A. 2007; 104(32):13092-7. PMC: 1941796. DOI: 10.1073/pnas.0702387104. View

14.

Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anestakis D, Zarogoulidis K . MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal. 2015; 27(8):1576-88. DOI: 10.1016/j.cellsig.2015.04.009. View

15.

Bianco R, Troiani T, Tortora G, Ciardiello F . Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer. 2005; 12 Suppl 1:S159-71. DOI: 10.1677/erc.1.00999. View

16.

Nelson K, Weiss G . MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008; 7(12):3655-60. DOI: 10.1158/1535-7163.MCT-08-0586. View

17.

Li Z, Rana T . Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014; 13(8):622-38. DOI: 10.1038/nrd4359. View

18.

Politi K, Fan P, Shen R, Zakowski M, Varmus H . Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech. 2009; 3(1-2):111-9. PMC: 2806903. DOI: 10.1242/dmm.003681. View

19.

Ma L, Weinberg R . Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 2008; 24(9):448-56. DOI: 10.1016/j.tig.2008.06.004. View

20.

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View